Literature DB >> 22332192

Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort.

Abhay Moghekar1, Joshua Goh, Ming Li, Marilyn Albert, Richard J O'Brien.   

Abstract

OBJECTIVE: To determine whether cerebrospinal fluid (CSF) biomarkers for Alzheimer disease fluctuate significantly over time in a cohort of older, mildly symptomatic individuals.
DESIGN: Biomarker validation in a clinical cohort.
SETTING: University hospital inpatient unit. PARTICIPANTS: Ten patients admitted for CSF drainage for diagnostic purposes. MAIN OUTCOME MEASURES: The CSF levels of Aβ1-40, Aβ1-42, tau, and phosphorylated tau on threonine 181 (p-tau(181)) were measured every 6 hours for 24 or 36 hours.
RESULTS: The mean coefficient of variation values for each biomarker assessed in our 10 patients were 5.5% (95% CI, 3.8%-10.0%) for Aβ1-42, 12.2% (9.0%-24.2%) for Aβ1-40, 8.2% (5.7%-15.1%) for total tau, and 11.9% (8.5%-23.0%) for p-tau(181). These values are only slightly higher than the variability in the assay. In addition, no significant circadian fluctuation in any Alzheimer disease biomarker was observed given the limitations of our sampling frequency.
CONCLUSION: In a cohort of elderly patients, little fluctuation in the levels of important Alzheimer disease biomarkers in lumbar CSF is seen as a function of time.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22332192      PMCID: PMC3310240          DOI: 10.1001/archneurol.2011.732

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  24 in total

1.  Biomarkers in Alzheimer's disease drug development.

Authors:  Kaj Blennow
Journal:  Nat Med       Date:  2010-09-21       Impact factor: 53.440

Review 2.  Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall.

Authors:  Niklas Mattsson; Kaj Blennow; Henrik Zetterberg
Journal:  Clin Chem Lab Med       Date:  2010-05       Impact factor: 3.694

3.  Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment.

Authors:  Ozioma C Okonkwo; Michelle M Mielke; H Randall Griffith; Abhay R Moghekar; Richard J O'Brien; Leslie M Shaw; John Q Trojanowski; Marilyn S Albert
Journal:  Arch Neurol       Date:  2011-01

Review 4.  Statins for the treatment of dementia.

Authors:  Bernadette McGuinness; John O'Hare; David Craig; Roger Bullock; Reem Malouf; Peter Passmore
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

5.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

6.  Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people.

Authors:  Geert De Meyer; Fred Shapiro; Hugo Vanderstichele; Eugeen Vanmechelen; Sebastiaan Engelborghs; Peter Paul De Deyn; Els Coart; Oskar Hansson; Lennart Minthon; Henrik Zetterberg; Kaj Blennow; Leslie Shaw; John Q Trojanowski
Journal:  Arch Neurol       Date:  2010-08

7.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Authors:  Robert C Green; Lon S Schneider; David A Amato; Andrew P Beelen; Gordon Wilcock; Edward A Swabb; Kenton H Zavitz
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

8.  Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease.

Authors:  A M Saunders; W J Strittmatter; D Schmechel; P H George-Hyslop; M A Pericak-Vance; S H Joo; B L Rosi; J F Gusella; D R Crapper-MacLachlan; M J Alberts
Journal:  Neurology       Date:  1993-08       Impact factor: 9.910

9.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422

10.  Revising the definition of Alzheimer's disease: a new lexicon.

Authors:  Bruno Dubois; Howard H Feldman; Claudia Jacova; Jeffrey L Cummings; Steven T Dekosky; Pascale Barberger-Gateau; André Delacourte; Giovanni Frisoni; Nick C Fox; Douglas Galasko; Serge Gauthier; Harald Hampel; Gregory A Jicha; Kenichi Meguro; John O'Brien; Florence Pasquier; Philippe Robert; Martin Rossor; Steven Salloway; Marie Sarazin; Leonardo C de Souza; Yaakov Stern; Pieter J Visser; Philip Scheltens
Journal:  Lancet Neurol       Date:  2010-10-09       Impact factor: 44.182

View more
  27 in total

1.  Long-term hydrocephalus alters the cytoarchitecture of the adult subventricular zone.

Authors:  Tania Campos-Ordoñez; Vicente Herranz-Pérez; Kaisorn L Chaichana; Jordina Rincon-Torroella; Daniele Rigamonti; Jose M García-Verdugo; Alfredo Quiñones-Hinojosa; Oscar Gonzalez-Perez
Journal:  Exp Neurol       Date:  2014-05-21       Impact factor: 5.330

2.  Serum tau concentration after diving - an observational pilot study.

Authors:  Anders Rosén; Nicklas Oscarsson; Andreas Kvarnström; Mikael Gennser; Göran Sandström; Kaj Blennow; Helen Seeman-Lodding; Henrik Zetterberg
Journal:  Diving Hyperb Med       Date:  2019-06-30       Impact factor: 0.887

3.  Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.

Authors:  Corinne Pettigrew; Anja Soldan; Abhay Moghekar; Mei-Cheng Wang; Alden L Gross; Richard O'Brien; Marilyn Albert
Journal:  Neuropsychologia       Date:  2015-09-21       Impact factor: 3.139

4.  Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior.

Authors:  Anja Soldan; Corinne Pettigrew; Abhay Moghekar; Marilyn Albert
Journal:  J Int Neuropsychol Soc       Date:  2016-11       Impact factor: 2.892

5.  Progressive apraxic agraphia with micrographia presenting as corticobasal syndrome showing extensive Pittsburgh compound B uptake.

Authors:  Yasuhisa Sakurai; Kenji Ishii; Masahiro Sonoo; Yuko Saito; Shigeo Murayama; Atsushi Iwata; Kensuke Hamada; Izumi Sugimoto; Shoji Tsuji; Toru Mannen
Journal:  J Neurol       Date:  2013-04-16       Impact factor: 4.849

6.  Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change.

Authors:  Anja Soldan; Corinne Pettigrew; Qing Cai; Mei-Cheng Wang; Abhay R Moghekar; Richard J O'Brien; Ola A Selnes; Marilyn S Albert
Journal:  JAMA Neurol       Date:  2016-06-01       Impact factor: 18.302

Review 7.  Immunity's fourth dimension: approaching the circadian-immune connection.

Authors:  Alvaro Arjona; Adam C Silver; Wendy E Walker; Erol Fikrig
Journal:  Trends Immunol       Date:  2012-09-20       Impact factor: 16.687

Review 8.  Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; Richard J Perrin
Journal:  Biomark Med       Date:  2012-08       Impact factor: 2.851

9.  Relationship of cognitive reserve and cerebrospinal fluid biomarkers to the emergence of clinical symptoms in preclinical Alzheimer's disease.

Authors:  Anja Soldan; Corinne Pettigrew; Shanshan Li; Mei-Cheng Wang; Abhay Moghekar; Ola A Selnes; Marilyn Albert; Richard O'Brien
Journal:  Neurobiol Aging       Date:  2013-08-01       Impact factor: 4.673

Review 10.  Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.

Authors:  Piotr Lewczuk; Peter Riederer; Sid E O'Bryant; Marcel M Verbeek; Bruno Dubois; Pieter Jelle Visser; Kurt A Jellinger; Sebastiaan Engelborghs; Alfredo Ramirez; Lucilla Parnetti; Clifford R Jack; Charlotte E Teunissen; Harald Hampel; Alberto Lleó; Frank Jessen; Lidia Glodzik; Mony J de Leon; Anne M Fagan; José Luis Molinuevo; Willemijn J Jansen; Bengt Winblad; Leslie M Shaw; Ulf Andreasson; Markus Otto; Brit Mollenhauer; Jens Wiltfang; Martin R Turner; Inga Zerr; Ron Handels; Alexander G Thompson; Gunilla Johansson; Natalia Ermann; John Q Trojanowski; Ilker Karaca; Holger Wagner; Patrick Oeckl; Linda van Waalwijk van Doorn; Maria Bjerke; Dimitrios Kapogiannis; H Bea Kuiperij; Lucia Farotti; Yi Li; Brian A Gordon; Stéphane Epelbaum; Stephanie J B Vos; Catharina J M Klijn; William E Van Nostrand; Carolina Minguillon; Matthias Schmitz; Carla Gallo; Andrea Lopez Mato; Florence Thibaut; Simone Lista; Daniel Alcolea; Henrik Zetterberg; Kaj Blennow; Johannes Kornhuber
Journal:  World J Biol Psychiatry       Date:  2017-10-27       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.